Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;36:233-238

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reddi, A. S.
Right arrow Articles by Bollineni, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reddi, A. S.
Right arrow Articles by Bollineni, J. S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes
*Diabetic Kidney Problems
*High Blood Pressure
Hazardous Substances DB
*DOXAZOSIN MESYLATE
*LISINOPRIL
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Angiogenesis

(Hypertension. 2000;36:233.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Effect of Antihypertensive Therapy on Renal Injury in Type 2 Diabetic Rats With Hypertension

Alluru S. Reddi; Venkata R. Nimmagadda; Aza Lefkowitz; Hon-Reen Kuo; Jaya S. Bollineni

From the Department of Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark.

Correspondence to A.S. Reddi, MD, PhD, Department of Medicine, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 S Orange Ave, Newark, NJ 07103. E-mail reddias{at}umdnj.edu

Abstract—In a previous study, we demonstrated that doxazocin (DZN), an {alpha}1-adrenergic blocker, prevented proteinuria in streptozotocin diabetic rats. In this study, we investigated whether DZN would lower established proteinuria by improving glomerular sclerosis in spontaneously hypertensive corpulent rats with type 2 diabetes mellitus. DZN treatment was compared with treatment with angiotensin-converting enzyme inhibitor, lisinopril (LIS) alone, and DZN in combination with LIS. Combination therapy was used to examine any additive effect of either drug alone in the reduction of proteinuria and glomerular sclerosis. Both male and female rats age 6 months with established proteinuria were used. The rats were allocated randomly to 1 of 4 groups: untreated, DZN treated, LIS treated, or a combination of DZN and LIS treatment. Drug treatment was continued for 16 weeks. The results show that (1) either drug alone or in combination significantly lowered systolic blood pressure; (2) DZN, LIS, or combination therapy reduced albuminuria at 16 weeks of treatment from baseline by 38.61±5.77%, 30.70±4.21%, and 42.17±4.77% (mean±SE), respectively. No difference in albuminuria was observed among the 3 groups of rats; (3) the fractional mesangial area, which was 20.55±3.77% in untreated rats, was significantly reduced to 11.18±1.32% in DZN-treated rats, with a further reduction to 8.72±0.64% in LIS-treated rats and to 3.48±0.35% in rats treated with DZN+LIS; and (4) DZN but not LIS significantly improved plasma glucose levels in spontaneously hypertensive corpulent rats (untreated 21.06±0.97 mmol/L versus DZN treated 15.81±0.93 mmol/L or DZN+LIS treated 17.38±1.10 mmol/L; P<0.025 to 0.005). Thus, the data suggest that 16-week treatment with either DZN or LIS improves established proteinuria and glomerular sclerosis, but combination therapy is superior to either DZN or LIS alone in preventing glomerular sclerosis in type 2 diabetic rats with hypertension.


Key Words: diabetic nephropathy • rats, spontaneously hypertensive • adrenergic receptor blocker • antihypertensive agents • angiotensin-converting enzyme inhibitors • albuminuria • glomerulosclerosis




This article has been cited by other articles:


Home page
HypertensionHome page
J. A. Joles and H. A. Koomans
Causes and Consequences of Increased Sympathetic Activity in Renal Disease
Hypertension, April 1, 2004; 43(4): 699 - 706.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
H. A. Koomans, P. J. Blankestijn, and J. A. Joles
Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call
J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. S. Reddi, V. R. Nimmagadda, and R. Arora
Effect of Antihypertensive Therapy on Renal Artery Structure in Type 2 Diabetic Rats With Hypertension
Hypertension, May 1, 2001; 37(5): 1273 - 1278.
[Abstract] [Full Text] [PDF]